Aflibercept injection phase II results for ME patients

Article

The VEGF Trap-Eye is well-tolerated in patients suffering from macula oedema.

The VEGF Trap-Eye is well tolerated in patients suffering from macula oedema, according to results of the GALILEO Study presented at the 2012 World Ophthalmology Congress in Abu Dhabi.

VEGF Trap-Eye, a fully human fusion protein, was injected in the eyes of 104 randomized ME patients (Group 1), with 68 ME patients randomized to the control group (Group 2). Group 1 received 2 mg injections of VEGF Trap-Eye four times a week for 24 weeks. Group 2 received sham injections for 52, and switched to active therapy until week 76. After six months all patients in the VEGF group were given PRN for a further six months.

Overall, VEGF Trap-Eye was well-tolerated and successful in treating patients with ME. Group 1 demonstrated a mean gain of 18 letters, compared to a mean gain of 3.3 letters in group 2.

Of the patients administered treatment in group 1, 60.2% gained at least 15 letters from baseline to week 52. This is compared to 32.4% in the control group. Treated patients gained a mean of 16.9 letters of vision compared to an average gain of 3.8 letters in the control group.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
© 2025 MJH Life Sciences

All rights reserved.